Biology Agriculture Aquaculture Horticulture Postharvest Forestry Geography Environment Health





Initial Clinical Experience With the HeartWare Left Ventricular Assist System: A Single-Center Report

submitted by olhochome 1 year and 8 months ago
The HeartWare ventricular assist device (HVAD) system (HeartWare International Inc, Framingham, MA) is a new centrifugal continuous-flow ventricular assist device. The aim of the present study is to review our institutional experience with this novel device. We reviewed the files of 50 patients (39 men, 11 women) with a mean age of 50.6 ± 11.8 years (range, 19 to 70 years) who underwent HVAD implantation between July 2009 and November 201Two patients underwent HeartWare BIVAD implantation. The underlying heart diseases were end-stage ischemic heart disease (n = 12), acute myocardial infarction (n = 9), dilated cardiomyopathy (n = 27) and acute myocarditis (n = 2). Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles were level 1 (n = 11), 2 (n = 5), 3 (n = 10), and 4 (n = 24). After a cumulative support duration of 11,086 days, Kaplan-Meier analysis revealed a survival of 82.0%, 77.9%, 75.5%, at 1, 12, and 24 months, respectively. Causes of early death were right heart failure (n = 4), multiorgan failure (n = 2), septic shock (n = 2), and major neurologic complications (n = 4). One late death occurred due to a right heart failure. Comparison between patients operated on in cardiogenic shock (INTERMACS 1 and 2) and patients who underwent elective HVAD implantation (INTERMACS 3 and 4) revealed a survival of 61.5% and 44.1% for the INTERMACS 1 and 2 group and 90.3% and 87.1% for the INTERMACS 3 and 4 group at 1 and 12 months, respectively (odds ratio, 4.67; p = 0.003). One patient was weaned from the system after 2 years. Eleven patients (22%) were successfully bridged to transplantation. Mean time to transplantation was 209 days (range, 72 to 427 days). Posttransplant survival at the 1-year follow-up was 90.9% (11 patients). Our experience with HVAD shows satisfying results with an excellent posttransplantation survival. Moreover, the stratified survival based on the level of preoperative stability shows better outcomes in patients undergoing elective HVAD implantation.


Topic: Health

Add your comment

Please Login or Signup to leave a comment

Related stories

Cardiovascular Pharmacogenomics: Expectations and Practical Benefits
submitted by sarish 5 months ago - Topic: Health
Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Pharmacogenomics is the study of genetic determinants of interindividual variation in drug response and aims to facilitate personalized medicine, through genotype-informed drug and dose selection, to maximize drug efficacy and/or minimize adverse drug reactions. Despite high expectations, no cardiovascular pharmacog...

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era
submitted by vejoykamor 1 year and 6 months ago - Topic: Health
Mortality for refractory cardiogenic shock (RCS) remains high. However, with improving mechanical circulatory support device (MCSD) technology, the treatment options for RCS patients are expanding. We report on a recent 5-year single-center experience with MCSD for treatment of RCS. This study was a retrospective review of adult patients who required an MCSD due to RCS in the past 5 years. We e...



Initial experience in Japan with HeartWare ventricular assist system
submitted by vencieadeco 5 months ago - Topic: Health
We describe the first clinical experiences in Japan with the HeartWare ventricular assist device (HVAD: HeartWare Inc., Miami Lakes, FL, USA) in patients awaiting heart transplantation. Nine patients (6 males, 3 females; mean 33.5 ± 7.8 years; New York Heart Association class III or IV) received the HVAD as a bridge to transplantation between 2011 and 2012. Six had dilated cardiomyopathy, 2...

Local Inhibition of MicroRNA-24 Improves Reparative Angiogenesis and Left Ventricle Remodeling and Function in Mice With Myocardial Infarction
submitted by rechisib 1 year and 1 month ago - Topic: Health
Myocardial infarction (MI) is the leading cause of death worldwide. MicroRNAs regulate the expression of their target genes, thus mediating a plethora of pathophysiological functions. Recently, miRNA-24 emerged as an important but controversial miRNA involved in post-MI responses. Here, we aimed at clarifying the effect of adenovirus-mediate intra-myocardial delivery of a decoy for miRNA-24 in ...


Transcatheter Aortic Valve Implantation by the Left Axillary Approach: A Single-Center Experience
submitted by ondriwrjb 5 months ago - Topic: Health
Transcatheter aortic valve implantation (TAVI) is an accepted alternative treatment for severe symptomatic aortic stenosis in high-risk and inoperable patients. Femoral or transapical accesses are commonly used. We report our initial clinical experience with TAVI using the left-axillary artery approach. A single-center, retrospective study of patients undergoing transaxillary TAVI between Janua...

Routine bacterial screening of apheresis platelets on Day 4 using a rapid test: a 4-year single-center experience
submitted by ozodfolloh 1 year and 5 months ago - Topic: Health
The platelet (PLT) Pan Genera Detection test (PGD) is a rapid bacterial detection system used to screen PLTs for bacterial contamination. We report a single center 46-month experience with secondary screening of apheresis PLTs by PGD testing. Existing testing records of apheresis PLTs screened by PGD from July 2008 to April 2012 were reviewed. All PLT units were initially screened by routine po...


Living donor liver transplantation in 43 children with biliary atresia: a single-center experience from the mainland of China
submitted by koangmyot12 2 years and 1 month ago - Topic: Health
There is no large-cohort report on living donor liver transplantation (LDLT) for biliary atresia (BA) patients from the mainland of China. This single-center study describes our initial experience with 43 LDLTs for BA patients aged two years or younger. In this study, the eligibility criteria were BA as the primary diagnosis and two years of age or younger. From October 26 to December 21, the c...

Single Institution's Dosimetry and IGRT analysis of prostate SBRT
submitted by trichas3111 10 months ago - Topic: Health
To report single institution's IGRT and dosimetry analysis on the 37Gy/5frcation prostate SBRT clinical trial. Materials/methods: The IRB (Duke University Medical Center) approved clinical trial has treated 28 patients with stage T1-T2c prostate cancer with a regimen of 37Gy in 5 fractions using IMRT and IGRT protocols since 2009. The clinical trial protocol requires CT/MRI imaging for the pros...


Single Institution’s Dosimetry and IGRT Analysis of Prostate SBRT
submitted by obroshen 8 months ago - Topic: Health
To report single institution’s IGRT and dosimetry analysis on the 37 Gy/5 fraction prostate SBRT clinical trial. The IRB (Duke University Medical Center) approved clinical trial has treated 28 patients with stage T1-T2c prostate cancer with a regimen of 37 Gy in 5 fractions using IMRT and IGRT protocols since 2009. The clinical trial protocol requires CT/MRI imaging for the prostate delineati...

Parkinson’s Disease Gene Therapy: Success by Design Meets Failure by Efficacy
submitted by rechisib 5 months ago - Topic: Health
Over the past decade, nine gene therapy clinical trials for Parkinson’s disease (PD) have been initiated and completed. Starting with considerable optimism at the initiation of each trial, none of the programs has yet borne sufficiently robust clinical efficacy or found a clear path toward regulatory approval. Despite the immediately disappointing nature of the efficacy outcomes in thes...